ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: PP09 • ACR Convergence 2024

    Finding the Balance: Regaining My Strength While Living with Sjögren’s & POTS

    Robert Fearon, Sjögren's Foundation, Reston, VA

    Background/Purpose: Like many suffering from autoimmune diseases, my diagnosis was not straightforward and took nearly 13 years to get answers. I first started experiencing an…
  • Abstract Number: PP16 • ACR Convergence 2024

    Utilization of My Knee Notes for Enhanced Healthcare Management

    Tien Sydnor-Campbell, Medically Retired, Philadelphia, PA

    Background/Purpose: Living with chronic knee issues for 40 years has been incredibly challenging. My knee pain began as early as 6th grade but got overlooked…
  • Abstract Number: PP05 • ACR Convergence 2024

    Reunion with Forgotten Relationships and Memories

    Noriko Okochi1, Eiji Oishi2, Kaoru Mitsuyama3, Emi Sorimachi3, Shiho Bando4, Yuka Hirama5, Nobuyuki Yajima6 and Masaaki Mori7, 1Rheumatic Disease and Vasculitis Support Network Japan, Tokyo, Japan, 2Rheumatic Disease and Vasculitis Support Network Japan, Yamaguchi, Japan, 3Institute of Neuropsychiatry, Tokyo, Tokyo, Japan, 4Ota-ku Children and Families Support Center, Ota-ku, Tokyo, Japan, 5Asada Ladies Clinic, Shinagawa, Japan, Tokyo, Japan, 6Showa-Universtiy of Medicine, Tokyo, Japan, 7Tokyo Medical and Dental University, Tokyo, Japan

    Background/Purpose: Paediatric rheumatic diseases are complex experiences for children.  For children whose language skills are still undeveloped, it is difficult for them to put their…
  • Abstract Number: 2683 • ACR Convergence 2024

    Optical Coherence Angiography: A Non-invasive, Safe Method for Assessing the Systemic Sclerosis Related Vasculopathy Beyond Nailfold Capillaries

    Pavel Nikitin1, Harshdeep Chawla1, Manmohan Singh1, Samuel Theodore2, Salavat Aglyamov1, Meng Zhang2, Brian Skaug2, Maureen Mayes2, Kirill Larin1 and Shervin Assassi2, 1University of Houston, Houston, TX, 2UTHealth Houston Division of Rheumatology, Houston, TX

    Background/Purpose: Vascular involvement is a prominent feature of systemic sclerosis (SSc). Safe and non-invasive methods to visualize cutaneous blood vessels beyond nailfold capillaries are lacking.…
  • Abstract Number: 2673 • ACR Convergence 2024

    Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis

    Diane Lacaille1, Coraline Danieli2, Kasra Moolooghy1 and Michal Abrahamowicz3, 1Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 2Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, 3McGill University, Verdun, Canada

    Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
  • Abstract Number: 2685 • ACR Convergence 2024

    Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project

    Arissa Young1, Kristofer Andreasson2, Swapna Joshi3, Jen Labus3, Andrea Low Hsiu Ling4, vanessa smith5, Zsuzsanna McMahan6, Antonia Valenzuela Vergara7, Susanna Proudman8, Grace Kim3, Gracijela Bozovic2, Jonathan Goldin3, Ezinne Aja3, Jonathan Jacobs3 and Elizabeth Volkmann9, 1UCLA, Los Angeles, CA, 2Lund University, Lund, Sweden, 3UCLA, Los Angeles, 43Singapore General Hospital, Duke-NUS, Singapore, Singapore, 5Ghent University Hospital, Gent, Belgium, 6UTHealth Houston Division of Rheumatology, Houston, TX, 7Pontificia Universidad Catolica de Chile, Santiago, Chile, 8Royal Adelaide Hospital, Adelaide, Australia, 9University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles

    Background/Purpose: Variations in gastrointestinal (GI) microbial communities may influence the development of lung diseases. Patients with SSc-ILD have a unique intestinal microbial signature. To further…
  • Abstract Number: 2689 • ACR Convergence 2024

    Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis

    Lynn Fussner1, Ivan Bilic2, Carol McAlear3, David Cuthbertson4, Jie Cheng5, Elise Chen5, Markus Weiller2, Ulrich Specks6 and Peter Merkel3, and for the Vasculitis Clinical Research Consortium, 1The Ohio State University, Columbus, OH, 2Takeda Pharmaceuticals, Vienna, Austria, 3University of Pennsylvania, Philadelphia, PA, 4University of South Florida, Tampa, FL, 5Takeda Pharmaceuticals, Cambridge, MA, 6Mayo Clinic, Rochester, MN

    Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
  • Abstract Number: PP03 • ACR Convergence 2024

    How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities

    Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI

    Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
  • Abstract Number: PP07 • ACR Convergence 2024

    My Journey with Diffuse Scleroderma and Interstitial Lung Disease: A Pharmacist’s Perspective

    Joseph Washington, Cencora, Washington, DC

    Background/Purpose: Since my diagnosis with diffuse scleroderma and ILD, I have balanced the roles of patient and young pharmacist. A duality that has surely impacted…
  • Abstract Number: 2688 • ACR Convergence 2024

    HLA-DRB4: A Novel Susceptibility Locus in Systemic Sclerosis Patients with Severe Calcinosis

    Sara Faghihi-Kashani1, srijana davluri2, Kamini Kuchinad3, Zuoming deng4, Faiza Naz4, Stefania Dell'Orso4, Zsuzsanna McMahan5, Laura Hummers6, Daniel Kastner7, Fredrick Wigley3, david fiorentino8, Christian Lood9, Ami Shah10, Lorinda Chung11 and Pravitt Gourh4, 1Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, Sunnyvale, CA, 3Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, 4National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, 5UTHealth Houston Division of Rheumatology, Houston, TX, 6Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, 7National Human Genome Research Institute, Bethesda, MD, Bethesda, MD, 8Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, 9Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, 10Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 11Stanford University, Woodside, CA

    Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease. Class II HLA alleles have been reported to play an important role in SSc pathogenesis. Calcinosis, deposition of…
  • Abstract Number: 2692 • ACR Convergence 2024

    Transcriptomic Profiling of Kidney Biopsies Implicates Th17 and IL-17 in ANCA-Associated Vasculitis

    Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan4, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Brad Rovin3, Samir Parikh5, Stacy Ardoin6, Daniel Koboldt7, James Fitch7 and Salem Almaani8, 1Nationwide, Columbus, OH, 2Feinstein Institutes for Medical Research, Melrose, MA, 3The Ohio State University, Columbus, OH, 4The Ohio State University, Columbus, 5Ohio State University, Columbus, OH, 6Nationwide Children's Hospital, Columbus, OH, 7Steve and Cindy Rasmussen Institute for Genomic Medicine, Columbus, OH, 8The Ohio State University Medical Center, Columbus, OH

    Background/Purpose: ANCA-associated vasculitis (AAV) is a severe autoimmune disease targeting small vessels, with significant kidney involvement. Despite current therapies, up to 28% of patients progress…
  • Abstract Number: 2691 • ACR Convergence 2024

    Transcriptomic Changes in CD4+ T Lymphocytes in Eosinophilic Granulomatosis with Polyangiitis

    Roberto Ríos-Garcés1, Núria Farran1, Salvador Naranjo-Suarez2, Roser Alba-Rovira1, Sergio Prieto-González3, Itziar Tavera-Bahillo1, Roser Solans-Laqué4, Ebymar Arismendi5, Marc Corbera-Bellalta1, Javi Marco-Hernández1, Farah Kamberovic1, Nina Visocnik1, Maria Cid6 and Georgina Espígol-Frigolé1, 1Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 2Angiogenesis in Liver Disease Research Group, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain, 3Vasculitis Research Group, Autoimmune Diseases Department, IDIBAPS, Hospital Clinic, University of Barcelona, bar, Spain, 4Internal Medicine Service, Vall d'Hebron Hospital University and Campus, Barcelona, Spain, 5Pneumology Department, Hospital Clinic, IDIBAPS, University of Barcelona, CIBERES, Barcelona, Spain, 6Hospital Clinic Barcelona. University of Barcelona, Barcelona, Spain

    Background/Purpose: Eosinophilic Granulomatosis with polyangiitis (EGPA) is a rare systemic autoimmune disorder, included within the ANCA-associated vasculitis. It is characterized by a diverse clinical profile,…
  • Abstract Number: 0159 • ACR Convergence 2024

    Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus

    Jianing Yang1, Jinoos Yazdany2, S. Sam Lim3, Brad Pearce3 and Laura Plantinga4, 1Highland Hospital, AHS, San Leandro, CA, 2UCSF, San Francisco, CA, 3Emory University, Atlanta, GA, 4University of California, San Francisco, San Francisco, CA

    Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
  • Abstract Number: 0152 • ACR Convergence 2024

    Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases

    Janett Riega Torres1, Karina Palomo-Arnaud2, Gabriel Figueroa-Parra1, Fernando Morales Wong1, Jesús Hernán González Cortés1, Jesus Mohamed Hamsho1, Jorge Esquivel-Valerio1, Dionicio Galarza-Delgado3 and Karim Mohamed Noriega1, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 3UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology.  Retinal toxicity is an unwanted side effect…
  • Abstract Number: 0168 • ACR Convergence 2024

    Real-world Glucocorticoid Prescription Patterns in Patients with Lupus Nephritis: A Retrospective Study Using a Healthcare Insurance Claims Database

    Tatsuya Atsumi1, Hironari Hanaoka2, Nobuo Nishijima3, Kohji Murakami4, Mariko Nio3, Tsutomu Urakawa3, Takaaki Fujimura3 and Hiroki Hayashi5, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, 4Nippon Shinyaku Co., Ltd., Tokyo, Japan, 5Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Background/Purpose: Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus (SLE), affecting morbidity and mortality in SLE. LN is…
  • « Previous Page
  • 1
  • …
  • 312
  • 313
  • 314
  • 315
  • 316
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology